Table 2.
Hyperglycemic Clamp Hormone and Substrate Profile During Normal Saline vs Intralipid Infusion
| African American |
American White |
P Value |
|||||
|---|---|---|---|---|---|---|---|
| Normal Saline | Intralipid | Normal Saline | Intralipid | Condition | Race | Interaction | |
| Baseline fasting | |||||||
| TG, mg/dL | 68.2 ± 9.6 | 1275.6 ± 183.1 | 117.0 ± 9.0 | 1409.2 ± 171.3 | <.001 | NS | NS |
| FFA, mmol/L | 0.3 ± 0.04 | 2.3 ± 0.2 | 0.3 ± 0.03 | 2.0 ± 0.2 | <.001 | NS | NS |
| Glucose, mg/dL | 93.3 ± 1.1 | 97.3 ± 1.4 | 95.9 ± 1.1 | 99.4 ± 1.3 | <.001 | NS | NS |
| Insulin, μU/mL | 24.2 ± 2.7 | 37.3 ± 6.8 | 23.6 ± 2.6 | 41.7 ± 6.5 | <.001 | NS | NS |
| C-peptide, ng/mL | 2.6 ± 0.2 | 3.9 ± 0.6 | 3.0 ± 0.2 | 5.0 ± 0.5 | <.001 | NS | NS |
| FOX, mg/kg · min | 0.7 ± 0.06 | 1.1 ± 0.07 | 0.8 ± 0.06 | 1.2 ± 0.07 | <.001 | NS | NS |
| GOX, mg/kg · min | 1.7 ± 0.2 | 1.2 ± 0.1 | 1.7 ± 0.2 | 1.3 ± 0.1 | .001 | NS | NS |
| First phase | |||||||
| TG, mg/dL | 68.3 ± 9.3 | 1232.9 ± 191.1 | 111.0 ± 8.7 | 1387.0 ± 178.8 | <.001 | NS | NS |
| FFA, mmol/L | 0.3 ± 0.03 | 2.3 ± 0.2 | 0.3 ± 0.03 | 2.0 ± 0.2 | <.001 | NS | NS |
| Glucose, mg/dL | 225.1 ± 1.9 | 223.5 ± 2.2 | 223.5 ± 1.8 | 226.9 ± 2.1 | NS | NS | NS |
| Insulin, μU/mL | 264.1 ± 29.9 | 277.6 ± 30.6 | 173.6 ± 28.6 | 186.4 ± 29.3 | NS | .03 | NS |
| C-peptide, ng/mL | 9.6 ± 0.8 | 10.7 ± 0.9 | 8.1 ± 0.7 | 9.8 ± 0.9 | <.001 | NS | NS |
| Second phase | |||||||
| TG, mg/dL | 64.3 ± 9.8 | 1163.9 ± 176.5 | 110.2 ± 9.2 | 1175.9 ± 165.1 | <.001 | NS | NS |
| FFA, mmol/L | 0.13 ± 0.02 | 2.1 ± 0.2 | 0.11 ± 0.02 | 1.9 ± 0.2 | <.001 | NS | NS |
| Glucose, mg/dL | 225.2 ± 0.7 | 226.9 ± 0.4 | 224.6 ± 0.6 | 226.6 ± 0.4 | .001 | NS | NS |
| Insulin, μU/mL | 256.8 ± 32.8 | 304.7 ± 42.4 | 220.4 ± 32.1 | 255.9 ± 41.5 | .004 | NS | NS |
| C-peptide, ng/mL | 11.5 ± 0.9 | 11.9 ± 1.0 | 11.8 ± 0.8 | 12.9 ± 1.0 | .02 | NS | NS |
Abbreviation: NS, not significant (P > .05). Data are means ± SEM.